Mira Pharmaceuticals Announces Board and Executive Changes
Ticker: MIRA · Form: 8-K · Filed: Nov 21, 2024 · CIK: 1904286
| Field | Detail |
|---|---|
| Company | Mira Pharmaceuticals, Inc. (MIRA) |
| Form Type | 8-K |
| Filed Date | Nov 21, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
TL;DR
Mira Pharma shakes up board and exec pay. Big changes coming?
AI Summary
Mira Pharmaceuticals, Inc. announced on November 18, 2024, a change in its board of directors and executive compensation arrangements. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for its key executives.
Why It Matters
Changes in a company's leadership and executive compensation can signal shifts in strategy or operational focus, potentially impacting future performance and investor confidence.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- Mira Pharmaceuticals, Inc. (company) — Registrant
- Florida (location) — State of Incorporation
- November 18, 2024 (date) — Date of earliest event reported
FAQ
Who departed from Mira Pharmaceuticals, Inc. as an officer or director?
The filing indicates the departure of certain officers and directors, but specific names are not provided in this summary section of the 8-K.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on November 18, 2024.
What is Mira Pharmaceuticals, Inc.'s principal executive office address?
The principal executive office is located at 1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131.
What is the company's telephone number?
The company's telephone number is (737) 289-0835.
What are the main items covered in this 8-K filing?
This 8-K filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
Filing Stats: 719 words · 3 min read · ~2 pages · Grade level 11.5 · Accepted 2024-11-21 16:15:24
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share MIRA The Nasdaq
Filing Documents
- form8-k.htm (8-K) — 37KB
- 0001493152-24-047146.txt ( ) — 212KB
- mira-20241118.xsd (EX-101.SCH) — 3KB
- mira-20241118_lab.xml (EX-101.LAB) — 33KB
- mira-20241118_pre.xml (EX-101.PRE) — 24KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MIRA PHARMACUTICALS, INC. Dated: November 21, 2024 By: /s/ Erez Aminov Name: Erez Aminov Title: Chief Executive Officer